Rigel Pharmaceuticals | RIGL - Sales Revenues

Stock Price
31.78
Daily Change
0.39 1.24%
Monthly
19.70%
Yearly
92.72%
Q2 Forecast
28.40

Rigel Pharmaceuticals reported $55.31M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celldex Therapeutics USD 121K 769K Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025